Cheminpharma-Allomek: A Modern Business Model for Funding Preclinical R&D

The Office of the Vice President for Research (OVPR) is pleased to share an opportunity to network with industry and scientists at an event sponsored by the BioscienceClubhouseCT, CURE – The Bioscience Network of CT, and featuring a graduate of UConn’s technology business incubator.

Join us at this Clubhouse event to hear Uday Khire, Founder and CEO of Cheminpharma LLC and Co-Founder of Allomek Therapeutics, share his experience managing two very different bio/pharma business operations, establishing funding for R&D, and his vision for the businesses. This will be an excellent opportunity for networking with the Connecticut Bioscience Community.

Cheminpharma LLC, a chemistry services company, applies a non-traditional business model of using revenues generated from their business to fund novel preclinical candidates, for example they have developed a novel compound which is showing promise in cardiomyopathy and a variety of cancers. Allomek Therapeutics, a spin-off company from Cheminpharma was established to focus on developing the above mentioned compound. Allomek has received pre-seed funding from Connecticut Innovations and was also awarded Phase I STTR in collaboration with Columbia University. Both Cheminpharma and Allomek were nominated to be a recipient for the “Most Promising Life Science Product” by CT Technology Council.

To register visit http://www.eventbrite.com/e/cheminpharma-allomek-a-modern-business-model-for-funding-preclinical-rd-tickets-12531854113

For further information, including car pools to the event, please contact Ana Fidantsef.